Fig S1-4; Table S1, S2, S4 and S5; S methods from Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer

Autor: Thomas A. Hughes, Eldo T. Verghese, Lucy F. Stead, Abeer M. Shaaban, Stacey J. Jones, Andrew M. Hanby, Sandra M. Bell, Diana E. Baxter, Lisa M. Allinson, Waleed S. Al Amri

Supplementary information concerning: laser capture microscopy (Fig S1), efficiency of siRNA knock-down (Fig S2), results of siRNA knock-down for ABC gene expression and function (Fig S3), abilities of MUC17 and PCNX1 expression to define patient out

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ac275e135431d4023f6231a8156b5e
https://doi.org/10.1158/1535-7163.22519101

Digital pathology for primary diagnosis of screen‐detected breast lesions – experimental data, validation and experience from four centres

Autor: Emad A. Rakha, Bethany Jill Williams, Justinas Besusparis, Darren Treanor, Anju Nijhawan, David Snead, Andrew M. Hanby, Imogen Wilson, Rebecca Millican-Slater, Eldo T. Verghese, David M. Clark

Publikováno v: Histopathology. 76:968-975

Aim The rate of deployment of digital pathology (DP) systems for primary diagnosis in the UK is accelerating. The flexibility and resilience of digital versus standard glass slides could be of great benefit in the NHS breast screening programme (NHSB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9e075b398c998d41050e820242fabbd
https://doi.org/10.1111/his.14079

Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer

Autor: Lucy F. Stead, Abeer M Shaaban, Stacey J. Jones, Lisa M. Allinson, Thomas A. Hughes, Sandra M. Bell, Andrew M. Hanby, Waleed S. Al Amri, Diana E. Baxter, Eldo T. Verghese

Publikováno v: Molecular Cancer Therapeutics. 19:945-955

Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted markers are not currently available. Treatment failure, in the form of recurrences, is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64df56d9e890c9b40aa368142d63158e
https://doi.org/10.1158/1535-7163.mct-19-0940

Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis.

Autor: Laura Smith, Euan W Baxter, Philip A Chambers, Caroline A Green, Andrew M Hanby, Thomas A Hughes, Claire E Nash, Rebecca A Millican-Slater, Lucy F Stead, Eldo T Verghese, Valerie Speirs

Publikováno v: PLoS ONE, Vol 10, Iss 10, p e0139698 (2015)

MicroRNA (miR) expression is commonly dysregulated in many cancers, including breast. MiR-92 is one of six miRs encoded by the miR-17-92 cluster, one of the best-characterised oncogenic miR clusters. We examined expression of miR-92 in the breast epi

Externí odkaz: https://doaj.org/article/4f8c107e3ba34a2abba7803a3bd0afe1

Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy

Autor: Baek Kim, Andrew H. Sims, Eldo T. Verghese, Andrew M. Hanby, Diana E. Baxter, Thomas A. Hughes

Publikováno v: Baxter, D E, Kim, B, Hanby, A M, Verghese, E T, Sims, A & Hughes, T A 2018, ' Neoadjuvant endocrine therapy in breast cancer up-regulates the cytotoxic drug pump ABCG2/BCRP, and may lead to resistance to subsequent chemotherapy ', Clinical breast cancer . https://doi.org/10.1016/j.clbc.2018.07.002, https://doi.org/10.1016/j.clbc.2018.07.002

Introduction Neoadjuvant treatments for primary breast cancer are becoming more common; however, little is known about how these impact on response to subsequent adjuvant therapies. Conveniently, neoadjuvant therapy provides opportunities to consider

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee61d91a32ee4dc5c58e64b26a1929cb
https://doi.org/10.1016/j.clbc.2018.07.002